Proximal tubular injury in myeloma

Contributions to Nephrology

Volumn 153, Issue , 2007, Pages 87-104

  Batuman, Vecihi ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN LIGHT CHAIN;

AMYLOIDOSIS; CHRONIC KIDNEY FAILURE; HUMAN; HYPERCALCEMIA; IMMUNOLOGY; INTERSTITIAL NEPHRITIS; KIDNEY PROXIMAL TUBULE; MULTIPLE MYELOMA; PATHOLOGY; PATHOPHYSIOLOGY; RENAL ARTERY; REVIEW; URINE;

AMYLOIDOSIS; HUMANS; HYPERCALCEMIA; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY FAILURE, CHRONIC; KIDNEY TUBULES, PROXIMAL; MULTIPLE MYELOMA; NEPHRITIS, INTERSTITIAL; RENAL ARTERY;

EID: 33751519297     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000096762     Document Type: Review

References (123)

1. Kyle RA: Multiple myeloma: an odyssey of discovery. Br J Haematol 2000;111:1035-1044.
2. Lin J, et al: Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001;12:1482-1492.
3. Ganeval D, Cathomen M, Noel LH, Grunfeld JP: Kidney involvement in multiple myeloma and related disorders. Contrib Nephrol 1982;33:210-222.
4. Defronzo RA, Humphrey RL, Wright JR, Cooke CR: Acute renal failure in multiple myeloma. Medicine (Baltimore) 1975;54:209-223.
5. Montseny JJ et al: Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant 1988;13:1438-1445.
6. DeFronzo RA, Cooke CR, Wright JR, Humphrey RL: Renal function in patients with multiple myeloma. Medicine (Baltimore) 1978;57:151-166.
7. Abbott KC, Agodoa LY: Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 2001;56:207-210.
8. Camargo MJ, Sumpio BE, Maack T: Kinetics of renal catabolism of absorbed proteins: influence of lysosomal pH. Contrib Nephrol 1984;42:19-29.
9. Maack T, Johnson V, Kau ST, Figueiredo J, Sigulem D: Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int 1979;16:251-270.
10. Clyne DH, Pollak VE: Renal handling and pathophysiology of Bence Jones proteins. Contrib Nephrol 1981;24:78-87.
11. Fang LS: Light-chain nephropathy. Kidney Int 1985;27:582-592.
12. Sanders PW, Herrera GA, Galla JH: Human Bence Jones protein toxicity in rat proximal tubule epithelium in vivo. Kidney Int 1987;32:851-861.
13. Park CH, Maack T: Albumin absorption and catabolism by isolated perfused proximal convoluted tubules of the rabbit. J Clin Invest 1984;73:767-777.
14. Batuman V, Guan S: Receptor-mediated endocytosis of immunoglobulin light chains by renal proximal tubule cells. Am J Physiol 1997;272:F521-F530.
15. Christensen EI, Birn H: Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule. Am J Physiol Renal Physiol 2001;280:F562-F573.
16. Batuman V, et al: Myeloma light chains are ligands for cubilin (gp280). Am J Physiol 1998;275:F246-F254.
17. Burmeister R, et al: A two-receptor pathway for catabolism of Clara cell secretory protein in the kidney. J Biol Chem 2001;276:13295-13301.
18. Verroust PJ, Birn H, Nielsen R, Kozyraki R, Christensen EI: The tandem endocytic receptors megalin and cubilin are important proteins in renal pathology. Kidney Int 2002;62:745-756.
19. Kozyraki R, et al: Megalin-dependent cubilin-mediated endocytosis is a major pathway for the apical uptake of transferrin in polarized epithelia. Proc Natl Acad Sci USA 2001;98:12491-12496.
20. Birn H, et al: Cubilin is an albumin binding protein important for renal tubular albumin reabsorption. J Clin Invest 2000;105:1353-1361.
21. Batuman V, Dreisbach AW, Cyran J: Light-chain binding sites on renal brush-border membranes. Am J Physiol 1990;258:F1259-F1265.
22. Sengul S, Zwizinski C, Batuman V: Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells. Am J Physiol Renal Physiol 2003;284:F1245-F1254.
23. Sengul S, et al: Endocytosis of light chains induces cytokines through activation of NF-κB in human proximal tubule cells. Kidney Int 2002;62:1977-1988.
24. Maniatis A: Pathophysiology of paraprotein production. Ren Fail 1998;20:821-828.
25. Tsai CY, Wu TH, Sun KH, Lin WM, Yu CL: Increased excretion of soluble interleukin 2 receptors and free light chain immunoglobulins in the urine of patients with active lupus nephritis. Ann Rheum Dis 1992;51:168-172.
26. Buxbaum J: Mechanisms of disease: monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease. Hematol Oncol Clin North Am 1992;6:323-346.
27. Preud'Homme JL, et al: Synthesis of abnormal heavy and light chains in multiple myeloma with visceral deposition of monoclonal immunoglobulin. Clin Exp Immunol 1980;42:545-553.
28. Preud'homme JL, et al: Synthesis of abnormal immunoglobulins in lymphoplasmacytic disorders with visceral light chain deposition. Am J Med 1980;69:703-710.
29. Messiaen T, et al: Adult Fanconi syndrome secondary to light chain gammopathy. Clinicopathologic heterogeneity and unusual features in 11 patients. Medicine (Baltimore) 2000;79:135-154.
30. Witzig TE, et al: Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies. J Clin Oncol 1988;6:1041-1046.
31. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-757.
32. Kyle RA, Rajkumar SV: Monoclonal gammopathies of undetermined significance. Rev Clin Exp Hematol 2002;6:225-252.
33. Kyle RA, et al: A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564-569.
34. Kyle RA, et al: Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc 2004;79:859-866.
35. Teppo AM, Groop L: Urinary excretion of plasma proteins in diabetic subjects. Increased excretion of kappa light chains in diabetic patients with and without proliferative retinopathy. Diabetes 1985;34:589-594.
36. Manuel Y, Colle A, Leclercq M, Tonnelle C: Low molecular weight proteinuria. Contrib Nephrol 1975;1:156-162.
37. Peterson PA, Berggard I: Urinary immunoglobulin components in normal, tubular, and glomerular proteinuria: quantities and characteristics of free light chains, IgG, igA, and Fc-gamma fragment. Eur J Clin Invest 1971;1:255-264.
38. Groop L, Makipernaa A, Stenman S, DeFronzo RA, Teppo AM: Urinary excretion of kappa light chains in patients with diabetes mellitus. Kidney Int 1990;37:1120-1125.
39. Perry MC, Kyle RA: The clinical significance of Bence Jones proteinuria. Mayo Clin Proc 1975;50:234-238.
40. Walton C, Bodansky HJ, Wales JK, Forbes MA, Cooper EH: Tubular dysfunction and microalbuminuria in insulin dependent diabetes. Arch Dis Child 1988;63:244-249.
41. Wahlstedt-Froberg V, Pettersson T, Aminoff M, Dugue B, Grasbeck R: Proteinuria in cubilin-deficient patients with selective vitamin B(12) malabsorption. Pediatr Nephrol 2003;18:417-421.
42. Tucker BJ, Rasch R, Blantz RC: Glomerular filtration and tubular reabsorption of albumin in pre-proteinuric and proteinuric diabetic rats. J Clin Invest 1993;92:686-694.
43. Christensen EI, Rennke HG, Carone FA: Renal tubular uptake of protein: effect of molecular charge. Am J Physiol 1983;244:F436-F441.
44. Solling K, Mogensen CE: Studies on the mechanism of renal tubular protein reabsorption. Proc Eur Dial Transplant Assoc 1977;14:543-549.
45. Mogensen CE, Solling K: Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids. Scand J Clin Lab Invest 1977;37:477-486.
46. Sanders PW, Herrera GA: Monoclonal immunoglobulin light chain-related renal diseases. Semin Nephrol 1993;13:324-341.
47. Nicastri AL, Brandao de Almeida Prado MJ, Sesso A, Brandao de Almeida Prado EB: Defective proximal tubule lysosomal acidification by Bence Jones proteins. An immunoelectron microscopy study. Exp Nephrol 1998;6:514-521.
48. Sanders PW, Herrera GA, Kirk KA, Old CW, Galla JH: Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobulin light chain deposition. Lab Invest 1991;64:527-537.
49. Ledingham JG: Tubular toxicity of filtered proteins. Am J Nephrol 1990;10:52-57.
50. Khamlichi AA, et al: Role of light chain variable region in myeloma with light chain deposition disease: evidence from an experimental model. Blood 1995;86:3655-3659.
51. Ying WZ, Sanders PW: Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am J Pathol 2001;158:1859-1866.
52. Venkataseshan VS, et al: Morphologic variants of light-chain deposition disease in the kidney. Am J Nephrol 1988;8:272-279.
53. Rocca A, et al: Sequences of V kappa L subgroup light chains in Fanconi's syndrome. Light chain V region gene usage restriction and peculiarities in myeloma-associated Fanconi's syndrome. J Immunol 1995;155:3245-3252.
54. Solomon A, Weiss DT, Kattine AA: Nephrotoxic potential of Bence Jones proteins. N Engl J Med 1991;324:1845-1851.
55. Alpers CE, Tu WH, Hopper J Jr, Biava CG: Single light chain subclass (kappa chain) immunoglobulin deposition in glomerulonephritis. Hum Pathol 1985;16:294-304.
56. Deret S, et al: Kappa light chain-associated Fanconi's syndrome: molecular analysis of monoclonal immunoglobulin light chains from patients with and without intracellular crystals. Protein Eng 1999;12:363-369.
57. Kirkpatrick CJ, Curry A, Galle J, Melzner I: Systemic kappa light chain deposition and amyloidosis in multiple myeloma: novel morphological observations. Histopathology 1986;10:1065-1076.
58. Comenzo RL, Zhang Y, Martinez C, Osman K, Herrera GA: The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood 2001;98:714-720.
59. Maldonado JE, et al: Fanconi syndrome in adults. A manifestation of a latent form of myeloma. Am J Med 1975;58:354-364.
60. Lacy MQ, Gertz MA: Acquired Fanconi's syndrome associated with monoclonal gammopathies. Hematol Oncol Clin North Am 1999;13:1273-1280.
61. Bate KL, Clouston D, Packham D, Ratnaike S, Ebeling PR: Lambda light chain induced nephropathy: a rare cause of the Fanconi syndrome and severe osteomalacia. Am J Kidney Dis 1998;32:E3.
62. Markowitz GS, Flis RS, Kambham N, D'Agati VD: Fanconi syndrome with free kappa light chains in the urine. Am J Kidney Dis 2000;35:777-781.
63. Johns EA, Turner R, Cooper EH, Maclennan IC: Isoelectric points of urinary light chains in myelomatosis: analysis in relation to nephrotoxicity. J Clin Pathol 1986;39:833-837.
64. Norden AG, Flynn FV, Fulcher LM, Richards JD: Renal impairment in myeloma: negative association with isoelectric point of excreted Bence-Jones protein. J Clin Pathol 1989;42:59-62.
65. Sanders PW, Herrera GA, Chen A, Booker BB, Galla JH: Differential nephrotoxicity of low molecular weight proteins including Bence Jones proteins in the perfused rat nephron in vivo. J Clin Invest 1988;82:2086-2096.
66. Smolens P, Venkatachalam M, Stein JH: Myeloma kidney cast nephropathy in a rat model of multiple myeloma. Kidney Int 1983;24:192-204.
67. Yokota N, et al: Renal tubular lesions induced by human Bence Jones protein in the rat: N-acetyl-beta-D-glucosaminidase as a sensitive marker. Int J Exp Pathol 1991;72:255-262.
68. Smithline N, Kassirer JP, Cohen JJ: Light-chain nephropathy. Renal tubular dysfunction associated with light-chain proteinuria. N Engl J Med 1976;294:71-74.
69. Batuman V, Sastrasinh M, Sastrasinh S: Light chain effects on alanine and glucose uptake by renal brush border membranes. Kidney Int 1986;30:662-665.
70. Batuman V, Guan S, O'Donovan R, Puschett JB: Effect of myeloma light chains on phosphate and glucose transport in renal proximal tubule cells. Ren Physiol Biochem 1994;17:294-300.
71. Guan S, el-Dahr S, Dipp S, Batuman V: Inhibition of Na-K-ATPase activity and gene expression by a myeloma light chain in proximal tubule cells. J Investig Med 1999;47:496-501.
72. Chan KW, Ho FC, Chan MK: Adult Fanconi syndrome in kappa light chain myeloma. Arch Pathol Lab Med 1987;111:139-142.
73. Thorner PS, Bedard YC, Fernandes BJ: Lambda-light-chain nephropathy with Fanconi's syndrome. Arch Pathol Lab Med 1983;107:654-657.
74. Yonemura K, Matsushima H, Kato A, Isozaki T, Hishida A: Acquired Fanconi syndrome associated with IgG kappa multiple myeloma: observations on the mechanisms of impaired renal acid excretion. Nephrol Dial Transplant 1997;12:1251-1253.
75. Pote A, Zwizinski C, Simon EE, Meleg-Smith S, Batuman V: Cytotoxicity of myeloma light chains in cultured human kidney proximal tubule cells. Am J Kidney Dis 2000;36:735-744.
76. Sanders PW, Herrera GA, Lott RL, Galla JH: Morphologic alterations of the proximal tubules in light chain-related renal disease. Kidney Int 1988;33:881-889.
77. Bridoux F, et al: Fanconi's syndrome induced by a monoclonal Vkappa3 light chain in Waldenstrom's macroglobulinemia. Am J Kidney Dis 2005;45:749-757.
78. Coward RA, Mallick NP, Delamore IW: Tubular function in multiple myeloma. Clin Nephrol 1985;24:180-185.
79. Lazar GS, Feinstein DI: Distal renal tubular acidosis in multiple myeloma. Arch Intern Med 1981;141:655-656.
80. Cohen AH: The kidney in plasma cell dyscrasias: Bence-Jones cast nephropathy and light chain deposit disease. Am J Kidney Dis 1998;32:529-532.
81. Hill GS, Morel-Maroger L, Mery JP, Brouet JC, Mignon F: Renal lesions in multiple myeloma: their relationship to associated protein abnormalities. Am J Kidney Dis 1983;2:423-438.
82. Iggo N, Winearls CG, Davies DR: The development of cast nephropathy in multiple myeloma [editorial]. QJM 1997;90:653-656.
83. Ivanyi B: Development of chronic renal failure in patients with multiple myeloma. Arch Pathol Lab Med 1993;117:837-840.
84. Ronco PM, Mougenot B, Touchard G, Preud'homme JL, Aucouturier P: Renal involvement in hematological disorders: monoclonal immunoglobulins and nephropathy. Curr Opin Nephrol Hypertens 1995;4:130-138.
85. Sanders PW, Booker BB: Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest 1992;89:630-639.
86. Start DA, Silva FG, Davis LD, D'Agati V, Pirani CL: Myeloma cast nephropathy: immunohistochemical and lectin studies. Mod Pathol 1988;1:336-347.
87. Vivaldi P, Comotti C, Pedrazzoli M: The kidney in multiple myeloma. The physiopathological and clinical aspects. Recent Prog Med 1994;85:123-133.
88. Sanders PW: Renal involvement in plasma cell dyscrasias. Curr Opin Nephrol Hypertens 1993;2:246-252.
89. Huang ZQ, Kirk KA, Connelly KG, Sanders PW: Bence Jones proteins bind to a common peptide segment of Tamm-Horsfall glycoprotein to promote heterotypic aggregation. J Clin Invest 1993;92:2975-2983.
90. Huang ZQ, Sanders PW: Biochemical interaction between Tamm-Horsfall glycoprotein and Ig light chains in the pathogenesis of cast nephropathy. Lab Invest 1995;73:810-817.
91. Huang ZQ, Sanders PW: Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein. J Clin Invest 1997;99:732-736.
92. Sakai Y, et al: Involvement of p38 MAP kinase pathway in the synergistic activation of PACAP mRNA expression by NGF and PACAP in PC12h cells. Biochem Biophys Res Commun 2001;285:656-661.
93. Arimura A, Li M, Batuman V: Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury. Blood 2006;107:661-668.
94. Goranov S: Acute renal failure in patients with multiple myeloma. Folia Med 1996;38:57-63.
95. Ivanyi B: Renal complications in multiple myeloma. Acta Morphol Hung 1989;37:235-243.
96. Mallick NP: Acute renal failure and myeloma. Nephrol Dial Transplant 1994;9:108-110.
97. Lasser EC, Lang JH, Zawadzki ZA: Contrast media. Myeloma protein precipitates in urography. JAMA 1966;198:945-947.
98. Holland MD, Galla JH, Sanders PW, Luke RG: Effect of urinary pH and diatrizoate on Bence Jones protein nephrotoxicity in the rat. Kidney Int 1985;27:46-50.
99. Dawnay AB, Thornley C, Nockler I, Webb JA, Cattell WR: Tamm-Horsfall glycoprotein excretion and aggregation during intravenous urography. Relevance to acute renal failure. Invest Radiol 1985;20:53-57.
100. Dawson P, Freedman DB, Howell MJ, Hine AL: Contrast-medium-induced acute renal failure and Tamm-Horsfall proteinuria. Br J Radiol 1984;57:577-579.
101. Rota S, et al: Multiple myeloma and severe renal failure: a clinicopathologic study of outcome and prognosis in 34 patients. Medicine (Baltimore) 1987;66:126-137.
102. McCarthy CS, Becker JA: Multiple myeloma and contrast media. Radiology 1992;183:519-521.
103. Kyle RA: Monoclonal proteins and renal disease. Annu Rev Med 1994;45:71-77.
104. Zucchelli P, Pasquali S, Cagnoli L, Ferrari G: Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 1988;33:1175-1180.
105. Buxbaum J, Gallo G: Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases. Hematol Oncol Clin North Am 1999;13:1235-1248.
106. Isaac J, et al: In vitro modulation of AL-amyloid formation by human mesangial cells exposed to amyloidogenic light chains. Amyloid 1998;5:238-246.
107. Gallo GR, et al: Nodular glomerulopathy associated with nonamyloidotic kappa light chain deposits and excess immunoglobulin light chain synthesis. Am J Pathol 1980;99:621-644.
108. Kanoh T, Yago K, Iwata H, Tei K, Higashino T: IgM-producing renal plasmacytoma. Urology 1992;40:484-488.
109. Sakhuja V, et al: Renal involvement in multiple myeloma: a 10-year study. Ren Fail 2000;22:465-477.
110. Clark AD, Shetty A, Soutar R: Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev 1999;13:79-90.
111. Alexanian R, Barlogie B, Dixon D: Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 1990;150:1693-1695.
112. Buxbaum JN, Chuba JV, Hellman GC, Solomon A, Gallo GR: Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis. Ann Intern Med 1990;112:455-464.
113. Irish AB, Winearls CG, Littlewood T: Presentation and survival of patients with severe renal failure and myeloma. QJM 1997;90:773-780.
114. Kitazawa R, et al: Expression of parathyroid hormone-related protein (PTHrP) in multiple myeloma. Pathol Int 2002;52:63-69.
115. Rosen L, Harland SJ, Oosterlinck W: Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors. Am J Clin Oncol 2002;25:S19-S24.
116. Saghafi D: Use of bisphosphonates in patients with myeloma and renal failure. Mayo Clin Proc 2003;78:118; author reply.
117. van Dijk JM, Sonnenblick M, Weissberg N, Rosin A: Pseudohypercalcemia and hyperviscosity with neurological manifestations in multiple myeloma. Isr J Med Sci 1986;22:143-144.
118. Barutcuoglu B, Parildar Z, Mutaf I, Habif S, Bayindir O: Spuriously elevated inorganic phosphate level in a multiple myeloma patient. Clin Lab Haematol 2003;25:271-274.
119. Adler SG, Laidlaw SA, Lubran MM, Kopple JD: Hyperglobulinemia may spuriously elevate measured serum inorganic phosphate levels. Am J Kidney Dis 1988;11:260-263.
120. Uchida M, Kamata K, Okubo M: Renal dysfunction in multiple myeloma. Intern Med 1995;34:364-370.
121. Waugh DA, Ibels LS: Multiple myeloma presenting as recurrent obstructive uropathy. Aust N Z J Med 1980;10:555-558.
122. Roth RM, Glovsky MM, Cooper JF 3rd, Douglas SD: Gamma A myeloma with hyperviscosity and obstructive uropathy. J Urol 1977;117:527-529.
123. Freel RJ, Maldonado JE, Gleich GJ: Hyperviscosity syndrome associated with immunoglobulin A myeloma. Am J Med Sci 1972;264:117-122.